BioCryst Pharmaceuticals, Inc.

Vir Biotechnology, Inc.VIR · BiotechSan Francisco, United States

68% matchPublicAI 8/100 ▼Green 0/100

Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.

Arrowhead Pharmaceuticals, Inc.0HI3 · BiotechPasadena, United States

68% matchPublicAI 11/100 ▲Green 3/100 ▲

Arrowhead Pharmaceuticals, Inc. is a U.S.-based company focused on developing innovative medicines for the treatment of challenging and difficult-to-treat diseases. The company's extensive development pipeline features several RNA interference (RNAi) therapeutic candidates. These include: ARO-AAT: Currently in Phase II clinical trials for liver diseases associated with alpha-1 antitrypsin deficiency. ARO-APOC3: Advancing through both Phase 2b and Phase 3 clinical studies for hypertriglyceridemia. ARO-ANG3: Undergoing Phase 2b clinical evaluation for dyslipidemia. ARO-HSD: Having successfully completed Phase 1/2 clinical trials for various liver diseases. ARO-ENaC2: In preclinical development for dyslipidemia linked to cystic fibrosis. ARO-C3: In Phase 1/2a clinical trials, designed to reduce the production of complement component 3. ARO-DUX4: A preclinical candidate targeting facioscapulohumeral muscular dystrophy. ARO-XDH: In Phase 1 clinical trials for refractory gout. ARO-COV: A preclinical program focused on COVID-19. ARO-RAGE: In Phase 1/2a clinical trials for muco-obstructive or inflammatory pulmonary conditions. ARO-MMP7: Also in Phase 1/2a clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). Beyond its proprietary programs, Arrowhead is actively involved in the development of other significant therapeutics: JNJ-3989: A subcutaneously administered RNAi therapeutic aimed at chronic hepatitis B virus infection. Olpasiran: Designed to decrease the synthesis of apolipoprotein A. ARO-AMG1: Targeting genetically validated pathways for cardiovascular disease. Arrowhead Pharmaceuticals maintains strategic licensing and research collaborations. It partners with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics JNJ-75220795, ARO-JNJ2, and ARO-JNJ3, all of which target liver-expressed pathways. Additionally, the company has a research and license agreement with Takeda Pharmaceuticals U.S.A., Inc. for an RNAi therapeutic candidate intended for liver disease. Established in 1989, Arrowhead Pharmaceuticals, Inc. operates from its corporate headquarters in Pasadena, California.

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.

Oragenics, Inc. is a biotechnology development-stage company incorporated in Florida in 1996 and headquartered in Lakewood Ranch, Florida. It is dedicated to fighting infectious diseases, including coronaviruses and multidrug-resistant pathogens.

Spero Therapeutics, Inc.SPRO · BiotechCambridge, United States

67% matchPublic

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.